Apelin-12 acetate

TargetMol
Product Code: TAR-T39823L
Supplier: TargetMol
CodeSizePrice
TAR-T39823L-1mg1mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39823L-5mg5mg£328.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39823L-10mg10mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39823L-25mg25mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39823L-1mL1 mL * 10 mM (in DMSO)£711.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39823L-50mg50mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39823L-100mg100mg£1,291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Apelin-12 acetate possesses a high affinity to orphan receptor APJ receptor. Apelin-12 acetate inhibits the JNK and p38 MAPK signaling pathway of the apoptosis-related MAPKs family, thus offering protection to neurons.
CAS:
T39823L
Formula:
C66H107N21O16S
Molecular Weight:
1482.75
Pathway:
GPCR/G Protein; MAPK
Purity:
0.9882
SMILES:
CC(O)=O.O=C([C@H]1N(CCC1)C([C@@H](N)CCCNC(N)=N)=O)N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H](C(N3CCC[C@H]3C(N[C@H](C(O)=O)CC4=CC=CC=C4)=O)=O)CCSC)=O)CCC2)=O)=O)CCCCN)=O)CC5=CN=CN5)=O)=O)=O)CCCNC(N)=N
Target:
Apelin receptor; p38 MAPK; JNK

References

Liu DR, Hu W, Chen GZ. Apelin-12 exerts neuroprotective effect against ischemia-reperfusion injury by inhibiting JNK and P38MAPK signaling pathway in mouse. Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3888-3895. Yin C, et al. Adropin and apelin-12 efficiently predict metabolic syndrome in obese children. Pediatr Diabetes. 2020 Nov;21(7):1132-1139.